Annemarie Moseley, COO/EVP Clinical Development at BELLICUM PHARMACEUTICALS, INC (BLCM), sold 35,000 shares at $21.33 ($722K) on 2015-07-01, disclosed to the SEC on 2015-07-06.
Scheduled sale ($722k) by COO/EVP Clinical Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.60 | 33,950 | $699K | 96.9% |
| 2 | $21.33 | 1,050 | $22K | 3.1% |
| Total | $20.62 avg | 35,000 | $722K | 100% |
| Filing → |
| BLCM | SELL | 2016-01-06 | $713K | — | Filing → |